CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade
Hiroko Yamakawa, Raghda Khatab, Akio Mizutani, Shunsuke Ebara, Takaharu Hirayama, Sunao Tanaka, Yusuke Tarumoto, Midori Sugiyama, Seiichi Sugino, Mariko Takano, Hidekazu Tokuhara, Toshio Tanaka, Hiroshi Banno, Yasuyoshi Arikawa, Yukiko Fukui, , Kosuke Yusa
This study develops CTX-439, a CDK12/13 inhibitor, showing anti-tumor effects and resistance mechanisms, and proposes combining it with BCL-2 family inhibitors for cancer treatment.
bioRxiv · Feb 20, 2026 · PreprintCancer Biology